Table 2.

Characteristics of seven P. aeruginosaisolates tested for carbapenemase production

No of isolateDate of isolation (mo/day/yr)DepartmentMaterialMIC (μg/ml) ofa:blaVIM status
IMMECZCFATCPGMANPI-TZb
478406/20/96C-SurgicalBlood>128>128>128>1283264>128>128>128+
482408/18/96A-ICUc Wound>128>128>128>1286464128>128>128+
488010/11/96C-ICUWound1280.5>128>1283216128128>128
495601/25/97A-ICUBronchial>128>128>128>12864128>128>128>128+
17406/12/97B-SurgicalUrine>128>128>128>1283264128128>128+
38810/03/97Dialysis UnitBlood>128128>128>1283264128128128+
55603/02/98C-SurgicalWound>128>128>128>12832128128128>128+
  • a IM, imipenem; ME, meropenem; CZ, ceftazidime; CF, cefepime; AT, aztreonam; CP, ciprofloxacin; GM, gentamicin; AN, amikacin; PI-TZ, piperacillin-tazobactam.

  • b Tazobactam tested at a fixed concentration of 4 μg/ml.

  • c ICU, intensive-care unit.